The Cost-Effectiveness Of Testing for Ns5a Resistance-Associated Polymorphisms at Baseline in Genotype I A-Infected (Treatment-Naive and Treatment-Experienced) Subjects Treated with All-Oral Elbasvir/ Grazoprevir Regimens in the United States

首页> 外文期刊>AIDS & hepatitis digest >The Cost-Effectiveness Of Testing for Ns5a Resistance-Associated Polymorphisms at Baseline in Genotype I A-Infected (Treatment-Naive and Treatment-Experienced) Subjects Treated with All-Oral Elbasvir/ Grazoprevir Regimens in the United States

【24h】

The Cost-Effectiveness Of Testing for Ns5a Resistance-Associated Polymorphisms at Baseline in Genotype I A-Infected (Treatment-Naive and Treatment-Experienced) Subjects Treated with All-Oral Elbasvir/ Grazoprevir Regimens in the United States

机译：在基因型中对基线的NS5A抗性相关多态性测试的成本效益Ia感染（治疗 - 幼稚和治疗经验丰富的）受试者在美国治疗的全口头埃尔巴斯韦/ Grazophir方案治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

This study showed that resistance-as-sociated variants (RAVs) testing-based strategy is superior to ombitasvir/ paritaprevir/ritonavir+dasabuvir (3D)+ ribavirin (RBV) or 8 weeks of ledi-pasvir/sofosbuvir (LDV/SOF) and is cost-effective compared with elbasvir/ grazoprevir (EBR/GZR) without testing. This conclusion is robust in several sensitivity analyses

机译：None

著录项

来源
《AIDS & hepatitis digest》 |2017年第1期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词

相似文献

外文文献

1. An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions [J] . Huang Chung-Feng, Hung Chao-Hung, Cheng Pin-Nan, The Journal of Infectious Diseases . 2019,第4期

机译：8次开放标签，随机，受体控制试验的8与Elbasvir / Grazoprevir用于治疗 - 天真慢性乙型肝炎基因型1B感染和轻度纤维化（享受纤维化）：基线病毒载荷和NS5A电阻相关的影响替换
2. Utilization and effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in treatment Naive (TN) genotype 1a (G1a) chronic hepatitis C virus (HCV) patients with/without baseline NS5A resistance-associated substitutions (RASs) [J] . Nwankwo C., Bacon B., Curry M., Journal of viral hepatitis. . 2018,第S2期

机译：Elbasvir / Grazoprevir（EBR / GZR）治疗Naive（TN）基因型1A（G1A）慢性丙型肝炎病毒（HCV）患者的利用和有效性/无基线NS5A抗性相关替代（RASS）
3. Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment Naive (TN) Genotype 1a (G1a) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A resistance-associated substitutions (RASs) [J] . Nwankwo Chizoba, Bacon Bruce, Curry Michael P., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：Elbasvir / GrazoPrevir（EBR / GZR）治疗Naive（TN）基因型1A（G1A）慢性丙型肝炎病毒（HCV）患者的利用和有效性/不含基线NS5A抗性相关替代（RASS）
4. The cost‐effectiveness of testing for NS5a resistance‐associated polymorphisms at baseline in genotype 1a‐infected (treatment‐naïve and treatment‐experienced) subjects treated with all‐oral elbasvir/grazoprevir regimens in the United States [O] . E. H. Elbasha, M. N. Robertson, C. Nwankwo -1

机译：在美国接受全口服Elbasvir / grazoprevir方案治疗的基因型1a感染（未接受过治疗和经历过治疗）的受试者在基线时检测NS5a耐药相关多态性的成本效益
5. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States [O] . E. H. Elbasha, M. N. Robertson, C. Nwankwo 2016

机译：在基因型1A感染（治疗 - 幼稚和治疗经验）受试者的基线上的NS5A抗性相关多态性测试的成本效益在美国治疗的基因型1A感染（治疗 - 幼稚和治疗）受试者。

The Cost-Effectiveness Of Testing for Ns5a Resistance-Associated Polymorphisms at Baseline in Genotype I A-Infected (Treatment-Naive and Treatment-Experienced) Subjects Treated with All-Oral Elbasvir/ Grazoprevir Regimens in the United States

摘要

著录项

相似文献

相关主题

期刊订阅